The first strike in fifteen years of existence
On the first of May, workers at Samsung Biologics — a company that had never before seen a general strike in its fifteen-year history — walked off production floors in Incheon, South Korea, seeking a share of prosperity they felt had passed them by. The dispute is not merely about percentages on a pay stub; it is about the older question of who bears the cost of building something large and who is permitted to benefit from it. With hundreds of millions of dollars in potential losses and global pharmaceutical supply chains in the balance, the outcome will be felt far beyond the factory gates.
- Workers demanding a 14% raise and a 30 million won bonus have forced a reckoning that thirteen rounds of failed negotiation could not produce — the company's counteroffer of 6.2% was simply not enough to hold the line.
- Samsung Biologics estimates a full work stoppage could erase more than $433 million — roughly half of a single quarter's earnings — turning every idle hour into a measurable wound on the balance sheet.
- A court partially intervened, restricting strike activity to six of nine production stages, but Samsung immediately appealed, arguing that even limited disruption threatens the strict process integrity demanded by the FDA and global regulators.
- The deeper danger is not financial alone: biopharmaceutical manufacturing tolerates almost no interruption, and any lapse in production standards ripples outward to hospitals and patients who depend on a steady, uncompromised supply of drugs.
- Both sides now face a narrowing window — the union's five-day strike mandate, the court's partial injunction, and the weight of global scrutiny are pressing toward a resolution neither party has yet been willing to offer.
On a Friday morning in late April, workers at Samsung Biologics staged the company's first general strike in fifteen years, walking off the job for five days over a compensation dispute that thirteen rounds of negotiation had failed to resolve.
The union's demands were substantial: a 14 percent increase in base pay, a matching rise in performance compensation, a one-time payment of 30 million won per worker, and annual bonuses tied to operating profit. Samsung — whose first-quarter sales had reached 1.26 trillion won — countered with a combined 6.2 percent increase. The gap between the two positions had not narrowed across months of talks, and the workers decided the moment had come to act.
The financial stakes were immediate and steep. The company estimated a complete stoppage could cost more than 640 billion won, roughly $433 million, and moved quickly to keep production moving with available management staff. Before the strike began, Samsung sought a full injunction in court; the court granted only a partial one, restricting strike activity across three of nine production stages while leaving the remaining six open. Samsung appealed at once.
The company's concern reached beyond lost revenue. Biopharmaceutical manufacturing operates under exacting regulatory standards — the FDA and other global bodies require unbroken process integrity at every stage of production. Even a limited disruption, analysts warned, could compromise finished drugs and send tremors through the global supply chains that hospitals and patients rely upon. What had begun as a wage dispute had grown into something with consequences well outside the walls of any single factory.
On a Friday morning in late April, workers at Samsung Biologics walked off the job. It was the first time in the company's fifteen-year history that unionized employees had staged a general strike, and they were prepared to stay out for five days. At stake was money—how much the company would pay them, and in what form.
Samsung Biologics, the biotech division of Samsung Group, had become a significant player in global pharmaceutical manufacturing. The company's first-quarter sales that year had reached 1.26 trillion won. But the workers who made that revenue possible felt they were not sharing fairly in the gains. The union was asking for a 14 percent raise in base pay, a matching 14 percent increase in performance-based compensation, a one-time cash payment of 30 million won per worker, and annual bonuses equal to 20 percent of operating profit. Samsung's counteroffer was far smaller: a combined 6.2 percent increase across base and performance pay. The two sides had met thirteen times between December and March. None of those conversations had closed the gap.
The strike's timing was deliberate and its stakes were high. Samsung Biologics estimated that a complete work stoppage could cost the company more than 640 billion won—roughly $433 million—representing about half of what it had earned in the previous quarter. The company moved quickly to limit the damage. Management deployed every available worker it could find to keep production moving. But the company's own statements made clear that some disruption was inevitable.
Before the strike began, Samsung had gone to court seeking an injunction to block it entirely. The court sided with the company partially. It issued an order restricting strike activity across three of the company's nine production stages, effectively keeping those lines running. The remaining six stages were left open for workers to strike. Samsung immediately appealed, arguing that even partial disruptions posed a serious risk. The company's concern was not merely financial. Industry analysts pointed out that biopharmaceutical manufacturing operates under strict regulatory oversight. The U.S. Food and Drug Administration and other global regulators require what they call "process integrity"—the assurance that every step of production meets exacting standards. Any interruption in the workflow, even in stages where workers were permitted to strike, could compromise the quality of finished drugs. That risk extended beyond Samsung's own bottom line. It touched the global supply chains that hospitals and patients depended on.
The workers, for their part, had decided that the moment had come to push back. Fifteen years of the company's existence had passed without a single strike. That silence had ended. What came next would depend on whether either side was willing to move significantly from its position.
Citas Notables
Samsung Biologics acknowledged that some impact to operations may be unavoidable despite deploying all available personnel— Samsung Biologics statement
Industry officials warned that disruptions at any production stage could affect product quality and regulatory compliance— Industry analysts
La Conversación del Hearth Otra perspectiva de la historia
Why did it take Samsung Biologics fifteen years to see its first strike?
The company was relatively new and growing fast. Workers may have been willing to accept the terms of employment while the business was establishing itself. But growth creates expectations—workers see the company succeeding and ask why their compensation hasn't kept pace.
The court allowed strikes in six of nine production stages. Why would Samsung appeal that?
Because in biopharmaceutical manufacturing, the stages are interconnected. If workers strike at stage five, it affects what happens at stage six and seven. The company isn't just worried about lost output—it's worried about product quality. A batch that moves through a disrupted process might not meet FDA standards.
Is 14 percent a reasonable ask?
That depends on context. If wages have been flat for years while the company's revenue has grown, 14 percent might be catching up. If the company is facing margin pressure, it might be unsustainable. The fact that they've met thirteen times without agreement suggests both sides have different views of what the company can afford.
What happens to patients if this strike drags on?
That's the real pressure point. If Samsung Biologics can't fulfill orders, other manufacturers might not be able to fill the gap quickly. Some patients might face delays in getting medications they depend on. That's why regulators care so much about process integrity—they want to know that disruptions don't create shortcuts that compromise safety.
Could this strike spread to other Samsung divisions?
That's a question hanging over the whole situation. If Biologics workers win significant gains, workers in other parts of Samsung might demand the same. If they lose badly, it might discourage labor organizing elsewhere. The outcome here sends a signal through the entire company.